A non-randomized confirmatory trial of segmentectomy for clinical T1N0 lung cancer with dominant ground glass opacity based on thin-section computed tomography (JCOG1211)
Authors:
- on behalf of the Lung Cancer Surgical Study Group of the Japan Clinical Oncology GroupOGon behalf of the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group
- Keiju AokageKAKeiju Aokage
- 2 March 2017
- journal article
- research article
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 65 (5) , 267-272
Abstract
Introduction Lobectomy has been the standard surgery for even stage I lung cancer since the validity of limited resection for stage I lung cancer was denied by the randomized study reported in 1995. The aim of this non-randomized confirmatory going on since September 2013 is to confirm the efficacy of a segmentectomy for clinical T1N0 lung cancer with dominant ground glass opacity based on thin-slice computed tomography. Method A total of 390 patients from 42 Japanese institutions are recruited within 4 years. The primary endpoint of this study is a 5-year relapse-free survival in all of the patients who undergo a segmentectomy for a lung nodule. The secondary endpoints are overall survival, annual relapse-free survival, disease-free survival, proportion of local relapse, postoperative pulmonary function, proportion of segmentectomy completion, proportion of R0 resection completion by segmentectomy, adverse events, and serious adverse events. This trial has been registered at the UMIN Clinical Trials Registry as UMIN000011819 (http://www.umin.ac.jp/ctr/). Results Patient’s accrual has been already finished in November, 2015 and the primary analysis will be performed in 2021. Conclusion This study is one of the pivotal trial of lung segmentectomy for early lung cancer. The result will provide a clear evidence for our daily clinics and will be possible contribution to preserving pulmonary function for lung cancer patients.Keywords
Funding Information
- the Japan Agency for Medical Research and Development, AMED. (15ck0106051h002)
- National Cancer Center Research and Development Fund (26-A-4)
This publication has 11 references indexed in Scilit:
- Radiographically determined noninvasive adenocarcinoma of the lung: Survival outcomes of Japan Clinical Oncology Group 0201The Journal of Thoracic and Cardiovascular Surgery, 2013
- Computed Tomography Screening for Lung Cancer: Has It Finally Arrived? Implications of the National Lung Screening TrialJournal of Clinical Oncology, 2013
- A Prospective Radiological Study of Thin-Section Computed Tomography to Predict Pathological Noninvasiveness in Peripheral Clinical IA Lung Cancer (Japan Clinical Oncology Group 0201)Journal of Thoracic Oncology, 2011
- A Phase III Randomized Trial of Lobectomy Versus Limited Resection for Small-sized Peripheral Non-small Cell Lung Cancer (JCOG0802/WJOG4607L)Japanese Journal of Clinical Oncology, 2009
- The proportion of consolidation to ground-glass opacity on high resolution CT is a good predictor for distinguishing the population of non-invasive peripheral adenocarcinomaLung Cancer, 2003
- “Early” peripheral lung cancer: prognostic significance of ground glass opacity on thin-section computed tomographic scanThe Annals of Thoracic Surgery, 2002
- Peripheral Lung Adenocarcinoma: Correlation of Thin-Section CT Findings with Histologic Prognostic Factors and SurvivalRadiology, 2001
- Bronchioloalveolar carcinoma: focal area of ground-glass attenuation at thin-section CT as an early sign.Radiology, 1996
- Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancerThe Annals of Thoracic Surgery, 1995
- Small adenocarcinoma of the lung. Histologic characteristics and prognosisCancer, 1995